Company Profile

Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).

Employees

Sector

Biotechnology & Medical Research

More about the company

24-01-31	Aravive, Inc.(NasdaqGS:ARAV) dropped from S&P TMI Index	CI
24-01-26	Aravive, Inc.(NasdaqGS:ARAV) dropped from NASDAQ Composite Index	CI
24-01-19	Wall Street Set to Open Higher Friday Ahead of Consumer Sentiment, Home Sales Data	MT
24-01-17	Aravive Shares Sink 53% After Hours on Plans to Voluntarily Terminate Listing on Nasdaq Global Select Market	MT
24-01-17	Aravive, Inc. Announces Termination of Rudy C. Howard as Chief Financial Officer	CI
24-01-17	Aravive, Inc. Announces Termination of Gail McIntrye as Chief Executive Officer	CI
24-01-17	Aravive, Inc. Announces Board and Committee Resignations	CI
23-11-09	Aravive, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-08-22	Cantor Fitzgerald Downgrades Aravive to Neutral From Overweight, Adjusts Price Target to $0.25 From $18	MT
23-08-21	Aravive, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-08-03	Top Midday Decliners	MT
23-08-03	EF Hutton Downgrades Aravive to Hold From Buy, Adjusts Price Target to $1 From $10	MT
23-08-03	HC Wainwright Downgrades Aravive to Neutral From Buy	MT

23-08-22	Cantor Fitzgerald Downgrades Aravive to Neutral From Overweight, Adjusts Price Target to $0.25 From $18	MT
23-08-03	EF Hutton Downgrades Aravive to Hold From Buy, Adjusts Price Target to $1 From $10	MT
23-08-03	HC Wainwright Downgrades Aravive to Neutral From Buy	MT
23-08-03	William Blair Downgrades Aravive to Market Perform From Outperform	MT
23-08-03	BTIG Downgrades Aravive to Neutral From Buy	MT

24-01-17	Aravive, Inc. to Delist from The Nasdaq Stock Market	AQ
23-10-19	The Street Reports: Guide to Penny Stocks Look Now! CLNV, ARAV, RDHL, ATHX, EPAZ	AQ
23-08-02	Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer	AQ
23-07-28	Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023	AQ
23-07-14	Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023	AQ

Manager	Title	Age	Since
Marek Ciszewski IRC	Investor Relations Contact	-	-
Maria Petrini PRN	Corporate Officer/Principal	-	2023-04-09

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/10/23	Maria Petrini	Free	Executive/Senior Manager	400,000	0.6684%
2/1/23	Robert B. Geller	Free	Chief Technology Officer	400,000	0.6686%
2/1/23	Leonard Dove	Free	Chief Operating Officer	400,000	0.6686%

Aravive, Inc. Stock

Stocks

ARAV

US03890D1081

Biotechnology & Medical Research

Latest news : Aravive, Inc.

Analysts' recommendations : Aravive, Inc.

Press Releases : Aravive, Inc.

Quotes and Performance

Managers and Directors : Aravive, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARAVIVE, INC.	-13.39%	-23.18%	-	-	2.95M
WUXI APPTEC CO., LTD.	-1.79%	-2.27%	+43.23%	+88.96%	67.98B
ARGENX SE	-2.06%	-0.18%	+39.67%	+86.44%	64.94B
INSMED INCORPORATED	-0.31%	+6.54%	-12.96%	+378.92%	27.58B
WUXI BIOLOGICS (CAYMAN) INC.	-3.00%	-2.90%	+33.13%	+12.54%	25.74B
BIONTECH SE	+0.86%	+1.65%	-7.74%	-14.95%	26.06B
GENMAB A/S	-1.46%	+0.42%	+23.61%	-18.61%	20.09B
PHARMAESSENTIA CORPORATION	-2.96%	-15.21%	+216.20%	+368.10%	17.16B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.49%	-4.88%	-6.60%	+531.89%	14.92B
EXELIXIS, INC.	-0.20%	+8.37%	+55.78%	+164.98%	14.62B
Average	-2.58%	+0.26%	+42.70%	+177.58%	31.01B
Weighted average by Cap.	-1.52%	+0.18%	+38.37%	+137.35%